NO20021567L - Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger - Google Patents
Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetningerInfo
- Publication number
- NO20021567L NO20021567L NO20021567A NO20021567A NO20021567L NO 20021567 L NO20021567 L NO 20021567L NO 20021567 A NO20021567 A NO 20021567A NO 20021567 A NO20021567 A NO 20021567A NO 20021567 L NO20021567 L NO 20021567L
- Authority
- NO
- Norway
- Prior art keywords
- acid
- polypeptide
- amino acid
- arginine
- variants
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 150000003839 salts Chemical group 0.000 abstract 8
- 235000001014 amino acid Nutrition 0.000 abstract 7
- 150000001413 amino acids Chemical class 0.000 abstract 7
- 239000004475 Arginine Substances 0.000 abstract 6
- 235000009697 arginine Nutrition 0.000 abstract 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 6
- 239000002253 acid Substances 0.000 abstract 5
- 239000002585 base Substances 0.000 abstract 5
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 4
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 abstract 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- 239000004472 Lysine Substances 0.000 abstract 3
- 150000007513 acids Chemical class 0.000 abstract 3
- 235000003704 aspartic acid Nutrition 0.000 abstract 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000012458 free base Substances 0.000 abstract 3
- 235000013922 glutamic acid Nutrition 0.000 abstract 3
- 239000004220 glutamic acid Substances 0.000 abstract 3
- 235000018977 lysine Nutrition 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 239000006172 buffering agent Substances 0.000 abstract 2
- 239000012669 liquid formulation Substances 0.000 abstract 2
- 239000001384 succinic acid Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15769699P | 1999-10-04 | 1999-10-04 | |
| PCT/US2000/027156 WO2001024814A1 (en) | 1999-10-04 | 2000-10-03 | Stabilized liquid polypeptide-containing pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20021567D0 NO20021567D0 (no) | 2002-04-03 |
| NO20021567L true NO20021567L (no) | 2002-05-22 |
Family
ID=22564882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021567A NO20021567L (no) | 1999-10-04 | 2002-04-03 | Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger |
| NO20044406A NO20044406L (no) | 1999-10-04 | 2004-10-15 | Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044406A NO20044406L (no) | 1999-10-04 | 2004-10-15 | Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US6525102B1 (zh) |
| EP (2) | EP1220682B1 (zh) |
| JP (2) | JP2003510368A (zh) |
| CN (2) | CN100389821C (zh) |
| AT (2) | ATE345810T1 (zh) |
| AU (2) | AU783306B2 (zh) |
| BR (2) | BRPI0017437B8 (zh) |
| CA (2) | CA2386228A1 (zh) |
| CZ (2) | CZ20021186A3 (zh) |
| DE (2) | DE60031999T2 (zh) |
| ES (1) | ES2276698T3 (zh) |
| HU (3) | HU0800692D0 (zh) |
| IL (3) | IL149008A0 (zh) |
| NO (2) | NO20021567L (zh) |
| NZ (2) | NZ535205A (zh) |
| PL (2) | PL211886B1 (zh) |
| PT (1) | PT1491208E (zh) |
| WO (1) | WO2001024814A1 (zh) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7006874B2 (en) * | 1996-01-05 | 2006-02-28 | Thermage, Inc. | Treatment apparatus with electromagnetic energy delivery device and non-volatile memory |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| PT1491208E (pt) * | 1999-10-04 | 2010-05-12 | Novartis Vaccines & Diagnostic | Composições farmacêuticas contendo polipéptido líquidas estabilizadas |
| PL356641A1 (en) * | 1999-12-30 | 2004-06-28 | Chiron Corporation | Methods for pulmonary delivery of interleukin-2 |
| US6495534B2 (en) | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
| JP4147234B2 (ja) | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| ATE365549T1 (de) * | 2001-03-23 | 2007-07-15 | Ajinomoto Kk | Mittel gegen stressinduzierte krankheiten |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| DE10149030A1 (de) * | 2001-10-05 | 2003-04-10 | Viscum Ag | Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin |
| WO2003055442A2 (en) | 2001-10-15 | 2003-07-10 | Chiron Corporation | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| US7842668B1 (en) | 2001-11-13 | 2010-11-30 | Genentech, Inc. | Apo-2 ligand/trail formulations |
| WO2003042344A2 (en) * | 2001-11-13 | 2003-05-22 | Genentech, Inc. | Apo2 ligand/trail formulations |
| EP3210624A1 (en) * | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| AU2003219958B2 (en) * | 2002-02-27 | 2006-01-05 | Immunex Corporation | Polypeptide formulation |
| US6964778B1 (en) * | 2002-09-06 | 2005-11-15 | Health Research, Inc. | Temperature controlled content release from liposomes |
| US6991805B1 (en) * | 2002-09-06 | 2006-01-31 | Health Research, Inc. | Temperature sensitive control of liposome-cell adhesion |
| AU2003268664A1 (en) * | 2002-09-26 | 2004-04-19 | Shionogi And Co., Ltd. | Stabilized protein compositions |
| ATE404176T1 (de) * | 2003-01-08 | 2008-08-15 | Novartis Vaccines & Diagnostic | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors |
| EP1803445A3 (en) * | 2003-01-08 | 2007-11-21 | Novartis Vaccines and Diagnostics, Inc. | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| SI1599222T1 (sl) * | 2003-01-08 | 2009-08-31 | Novartis Vaccines & Diagnostic | Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja |
| US20040208870A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| US20040208869A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Uses of anti-integrin alphanubeta3 antibody formulations |
| WO2004089335A2 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| US7445933B2 (en) * | 2003-07-16 | 2008-11-04 | Abbott Laboratories, Inc. | Stable calibrators or controls for measuring human natriuretic peptides |
| US7291501B2 (en) * | 2003-07-16 | 2007-11-06 | Abbott Laboratories | Stable compositions for measuring human natriuretic peptides |
| CA2535562A1 (en) * | 2003-08-13 | 2005-03-03 | Chiron Corporation | Improved method of purifying tfpi and tfpi analogs |
| US7141544B2 (en) | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| DE10348550A1 (de) * | 2003-10-20 | 2005-06-16 | Hexal Biotech Forschungsgmbh | Stabile wässrige G-CSF-haltige Zusammensetzungen |
| DK1682178T3 (da) | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet |
| US20050136542A1 (en) * | 2003-12-19 | 2005-06-23 | Beckman Coulter, Inc. | Stabilized liquid reference solutions |
| CA2551510C (en) | 2003-12-23 | 2013-07-30 | Pharmacia Corporation | Stable growth hormone liquid formulation |
| JPWO2005063291A1 (ja) * | 2003-12-25 | 2007-07-19 | 麒麟麦酒株式会社 | 抗体を含有する安定な水性医薬製剤 |
| WO2005067890A2 (en) * | 2004-01-13 | 2005-07-28 | Vasogenix Pharmaceuticals, Inc. | Controlled release cgrp delivery composition for cardiovascular and renal indications |
| US20090023644A1 (en) * | 2004-01-13 | 2009-01-22 | Southard Jeffery L | Methods of using cgrp for cardiovascular and renal indications |
| US20090023643A1 (en) * | 2004-01-13 | 2009-01-22 | Vasogenix Pharmaceuticals, Inc. | Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same |
| AU2005319099B2 (en) * | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
| EP1729791A2 (en) * | 2004-03-17 | 2006-12-13 | Chiron Corporation | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
| DK1729810T3 (en) * | 2004-04-02 | 2018-12-03 | Swedish Orphan Biovitrum Ab Publ | PROCEDURE FOR REDUCING AGGREGATION OF IL-1RA |
| JP4988562B2 (ja) * | 2004-06-01 | 2012-08-01 | アレス トレーディング ソシエテ アノニム | 安定化したインターフェロン液体製剤 |
| DE102004059776A1 (de) * | 2004-09-17 | 2006-04-06 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Brennstoffzellensystem |
| JP4147235B2 (ja) * | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置 |
| JP2008528509A (ja) * | 2005-01-21 | 2008-07-31 | アルザ コーポレイション | 少なくとも１つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤 |
| CN100336557C (zh) * | 2005-05-11 | 2007-09-12 | 北京双鹭药业股份有限公司 | 一种生长抑素的水溶液制剂、其制备方法及应用 |
| CN100337684C (zh) * | 2005-05-11 | 2007-09-19 | 北京双鹭药业股份有限公司 | 一种胸腺五肽的水溶液制剂、其制备方法及应用 |
| CN100342909C (zh) * | 2005-05-11 | 2007-10-17 | 北京双鹭药业股份有限公司 | 一种胸腺素α1的水溶液制剂、其制备方法及应用 |
| AU2006247188A1 (en) | 2005-05-18 | 2006-11-23 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against chlamydia infection |
| KR100769709B1 (ko) * | 2005-05-31 | 2007-10-23 | 주식회사 대웅 | 인성장호르몬을 함유하는 안정한 액상 제제 |
| EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| US20070191271A1 (en) * | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
| WO2007103425A2 (en) * | 2006-03-06 | 2007-09-13 | Novartis Ag | Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| GEP20125628B (en) * | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| CN105363022A (zh) * | 2006-07-06 | 2016-03-02 | 株式会社大熊 | 稳定的人生长激素液体制剂 |
| CN101505789A (zh) * | 2006-07-06 | 2009-08-12 | 株式会社大熊 | 稳定的人生长激素液体制剂 |
| US7923425B2 (en) * | 2006-08-21 | 2011-04-12 | Henkel Ag & Co. Kgaa | Low-foaming, acidic low-temperature cleaner and process for cleaning surfaces |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| KR20100111682A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
| CA2719272C (en) | 2008-03-26 | 2020-08-18 | Oramed Ltd. | Methods and compositions for oral administration of proteins |
| KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 ｇｌｐ－1 효능제의 병용물 |
| CN102281903B (zh) * | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 降低大分子在生理条件下聚集的方法和配方 |
| EP2403874A1 (en) * | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
| EP2451437B1 (de) * | 2009-07-06 | 2016-11-02 | Sanofi-Aventis Deutschland GmbH | Wässrige insulinzubereitungen enthaltend methionin |
| WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| NZ713967A (en) | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| HUE037735T2 (hu) | 2009-11-13 | 2018-09-28 | Sanofi Aventis Deutschland | DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény |
| KR101614983B1 (ko) * | 2009-11-17 | 2016-04-22 | 입센 파마 에스.에이.에스 | Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제 |
| EA201891433A3 (ru) | 2010-01-15 | 2019-02-28 | Кирин-Эмджен, Инк. | Состав антитела и терапевтические режимы |
| EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
| CA3101298A1 (en) | 2010-03-01 | 2011-09-09 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
| CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| EP2726495B1 (en) * | 2011-06-28 | 2019-03-06 | Leukocare Ag | Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide |
| RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| KR101759694B1 (ko) | 2011-10-28 | 2017-07-19 | 인테그리티 바이오, 아이엔씨. | 아미노산을 함유하는 단백질 제제 |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| JP6171331B2 (ja) * | 2012-12-25 | 2017-08-02 | 東ソー株式会社 | Ｆｃ結合性タンパク質の精製方法および定量方法 |
| JP2016505613A (ja) | 2013-01-03 | 2016-02-25 | オラムド エルティーディー． | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| CA3135558A1 (en) * | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Prevention of protein oxidation in a composition |
| US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
| US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
| KR102202476B1 (ko) | 2013-03-15 | 2021-01-12 | 제넨테크, 인크. | 세포 배양 배지 및 항체 생산 방법 |
| EP3043775B1 (en) | 2013-09-11 | 2020-11-04 | Eagle Biologics, Inc. | Liquid protein formulations containing viscosity-lowering agents |
| JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
| US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
| US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
| BR112016025866A2 (pt) | 2014-05-07 | 2017-12-12 | Applied Molecular Transp Llc | composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| KR102497368B1 (ko) | 2014-10-01 | 2023-02-10 | 이글 바이올로직스 인코포레이티드 | 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형 |
| JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン／リキシセナチド固定比処方 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6247241B2 (ja) * | 2015-02-27 | 2017-12-13 | ノバルティス アーゲー | 抗体処方 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP3287139B1 (en) * | 2015-04-21 | 2021-08-11 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Nerve growth factor composition and injection powder |
| KR20180098625A (ko) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
| WO2018038301A1 (en) * | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| JP6884858B2 (ja) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | 医薬製剤及びその製造方法 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| US20210137809A1 (en) * | 2017-06-14 | 2021-05-13 | Biosolution Co., Ltd | Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p |
| SG11202000210UA (en) * | 2017-08-08 | 2020-02-27 | Csl Behring Ag | Hemopexin formulations |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| WO2019173787A1 (en) | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| ES2920428T3 (es) | 2018-03-08 | 2022-08-03 | Applied Molecular Transport Inc | Constructos de administración derivados de toxinas para la administración oral |
| SG11202012299SA (en) * | 2018-06-13 | 2021-01-28 | Akron Biotechnology Llc | Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions |
| JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | ＭＡｄＣＡＭ標的化免疫寛容 |
| WO2021034727A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
| CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| BR112022013730A2 (pt) * | 2020-01-13 | 2022-10-11 | Aptevo Res & Development Llc | Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| TW202204387A (zh) * | 2020-03-31 | 2022-02-01 | 南韓商韓美藥品股份有限公司 | 新穎免疫刺激ｉｌ－２類似物 |
| CN117120070A (zh) * | 2021-03-11 | 2023-11-24 | 89生物公司 | 包含突变型fgf-21肽peg化缀合物的液体制剂 |
| EP4304625A1 (en) * | 2021-03-11 | 2024-01-17 | 89Bio, Inc. | Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates |
| CN117883376B (zh) * | 2024-03-14 | 2024-06-25 | 北京四环生物制药有限公司 | 含重组人白细胞介素-2的药物制剂及其制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| DE3583880D1 (de) | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
| JPS60215631A (ja) * | 1984-04-09 | 1985-10-29 | Takeda Chem Ind Ltd | インタ−ロイキン−２組成物 |
| US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
| US5034225A (en) * | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
| JPH0645551B2 (ja) * | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | インタ−ロイキン−２組成物 |
| US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| DE3782737T3 (de) | 1987-08-21 | 1999-05-20 | Imcera Group Inc | Stabilisierung von Wachstumshormonen. |
| US4883661A (en) | 1987-10-09 | 1989-11-28 | Daly John M | Use of arginine as an lymphokine synergist |
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| FR2684878B1 (fr) | 1991-12-12 | 1994-02-11 | Roussel Uclaf | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. |
| IL107887A (en) * | 1992-12-08 | 2003-07-06 | Ambi Inc | Stabilized lanthionine containing bacteriocin compositions |
| US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| DE69620877T2 (de) | 1995-02-06 | 2002-12-12 | Genetics Inst | Arzneimittelformulierungen für il-12 |
| ATE358684T1 (de) | 1995-06-07 | 2007-04-15 | Novartis Vaccines & Diagnostic | Waessrige formulierung enthaltend tfpi und lösungsvermittlers |
| US5888968A (en) * | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
| AU716785B2 (en) * | 1995-07-27 | 2000-03-09 | Genentech Inc. | Stabile isotonic lyophilized protein formulation |
| KR100408229B1 (ko) * | 1996-10-04 | 2003-12-01 | 암겐 인코포레이티드 | Ｍｐｌ 리간드를 함유하는 제약학적 조성물 |
| CA2279345A1 (en) * | 1997-01-31 | 1998-08-06 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
| PT1069912E (pt) | 1998-04-03 | 2007-09-14 | Novartis Vaccines & Diagnostic | Formulações injectáveis de igf contendo succinato como agente tampão |
| PT1491208E (pt) * | 1999-10-04 | 2010-05-12 | Novartis Vaccines & Diagnostic | Composições farmacêuticas contendo polipéptido líquidas estabilizadas |
| ATE300953T1 (de) | 2000-05-10 | 2005-08-15 | Novo Nordisk Healthcare Ag | Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| WO2002058734A2 (en) | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
-
2000
- 2000-10-03 PT PT04021066T patent/PT1491208E/pt unknown
- 2000-10-03 JP JP2001527813A patent/JP2003510368A/ja active Pending
- 2000-10-03 NZ NZ535205A patent/NZ535205A/en not_active IP Right Cessation
- 2000-10-03 PL PL370852A patent/PL211886B1/pl not_active IP Right Cessation
- 2000-10-03 CA CA002386228A patent/CA2386228A1/en not_active Abandoned
- 2000-10-03 US US09/677,643 patent/US6525102B1/en not_active Expired - Fee Related
- 2000-10-03 BR BRPI0017437A patent/BRPI0017437B8/pt not_active IP Right Cessation
- 2000-10-03 HU HU0800692A patent/HU0800692D0/hu unknown
- 2000-10-03 CA CA2477857A patent/CA2477857C/en not_active Expired - Lifetime
- 2000-10-03 EP EP00968584A patent/EP1220682B1/en not_active Expired - Lifetime
- 2000-10-03 DE DE60031999T patent/DE60031999T2/de not_active Expired - Lifetime
- 2000-10-03 WO PCT/US2000/027156 patent/WO2001024814A1/en active Application Filing
- 2000-10-03 BR BR0014486-0A patent/BR0014486A/pt not_active Application Discontinuation
- 2000-10-03 AU AU78475/00A patent/AU783306B2/en not_active Ceased
- 2000-10-03 EP EP04021066A patent/EP1491208B1/en not_active Expired - Lifetime
- 2000-10-03 IL IL14900800A patent/IL149008A0/xx unknown
- 2000-10-03 NZ NZ529856A patent/NZ529856A/en unknown
- 2000-10-03 PL PL00354987A patent/PL354987A1/xx not_active Application Discontinuation
- 2000-10-03 CN CNB2004100858470A patent/CN100389821C/zh not_active Expired - Lifetime
- 2000-10-03 CN CNB008163286A patent/CN1245216C/zh not_active Expired - Fee Related
- 2000-10-03 CZ CZ20021186A patent/CZ20021186A3/cs unknown
- 2000-10-03 ES ES00968584T patent/ES2276698T3/es not_active Expired - Lifetime
- 2000-10-03 HU HU0203133A patent/HUP0203133A3/hu unknown
- 2000-10-03 CZ CZ2004-1041A patent/CZ305123B6/cs not_active IP Right Cessation
- 2000-10-03 DE DE60044213T patent/DE60044213D1/de not_active Expired - Lifetime
- 2000-10-03 AT AT00968584T patent/ATE345810T1/de not_active IP Right Cessation
- 2000-10-03 AT AT04021066T patent/ATE464062T1/de not_active IP Right Cessation
- 2000-10-03 HU HU0401975A patent/HU227347B1/hu unknown
-
2002
- 2002-04-03 NO NO20021567A patent/NO20021567L/no not_active Application Discontinuation
- 2002-04-04 IL IL149008A patent/IL149008A/en active IP Right Grant
- 2002-11-18 US US10/299,039 patent/US7030086B2/en not_active Expired - Fee Related
-
2004
- 2004-10-15 NO NO20044406A patent/NO20044406L/no not_active Application Discontinuation
- 2004-10-29 JP JP2004317319A patent/JP2005068158A/ja active Pending
-
2005
- 2005-12-05 US US11/293,379 patent/US20060093598A1/en not_active Abandoned
- 2005-12-05 US US11/293,322 patent/US7807142B2/en not_active Expired - Fee Related
-
2006
- 2006-01-13 AU AU2006200141A patent/AU2006200141B2/en not_active Ceased
-
2007
- 2007-12-18 IL IL188230A patent/IL188230A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20021567D0 (no) | Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger | |
| MXPA03011041A (es) | Composiciones farmaceuticas que contienen orlistat y acidos grasos y/o sales de los mismos. | |
| EA200200938A1 (ru) | Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение | |
| HUP0204136A2 (hu) | Eljárások az interleukin-2 tüdőbe juttatására | |
| EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
| PT1589949E (pt) | Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares | |
| GEP20115206B (en) | Novel piperidine carboxylic acid amide derivatives | |
| RU2013150659A (ru) | Пероральное введение кальцитонина | |
| CA2480226A1 (en) | Stable pharmaceutical composition containing factor viii | |
| DK1588707T3 (da) | Stabilt fast medicinsk præparat til oral administration af ramosetron | |
| EA200401298A1 (ru) | Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение | |
| NO20020176L (no) | Sykliske peptidderivater som inhibitorer for intergrin <alfa>v<beta>6 | |
| BR0211060A (pt) | Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano | |
| TW200501963A (en) | Pharmaceutical compositions comprising epinastine for the treatment of skin diseases | |
| FR2846883B1 (fr) | Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide | |
| DE69918098D1 (de) | Neue suesstoffzusammensetzungen | |
| IL117816A0 (en) | N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them | |
| GEP20074100B (en) | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising the same | |
| DE69208171D1 (de) | Gallensäuren enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe | |
| KR900014429A (ko) | 폴리펩티드 유도체 및 칼슘 대사 향진제 | |
| JPH04270227A (ja) | ヒト組織プラスミノーゲン活性化因子含有組成物 | |
| IT1307866B1 (it) | Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento | |
| JPH08225459A (ja) | カルシトニンの注射用製剤 | |
| DK0817643T3 (da) | Forbindelser og præparater til administration af aktive midler | |
| TH45966A3 (th) | แอนตี้ฮิสตามีน ไซรัปที่เสถียร |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |